ERBB2 and breast cancer: Since pCR also plays an essential role in a long-term better outcome in the HR-positive/HER2-positive subgroup of BC patients [27,28], we explored the benefits of pCR improvement in the HR-positive/HER2-positive subgroup of the Zo-NAnTax trial.